3D VR and Indocyanine Green for Pulmonary Segmental Resection in NSCLC

This clinical trial is focused on improving a surgical technique called segmental resection for patients with early-stage non-small cell lung cancer (NSCLC). Typically, this type of surgery is very challenging due to the complex and varying anatomy of the lungs. It is difficult for surgeons to clearly see and separate the different parts of the lung during the operation. The current success rate for completing this surgery is about 60%, which is quite low. The study aims to enhance this procedure using 3-dimensional virtual reality (VR) modelling to help plan and conduct the surgery more effectively. The goal is to make this technique more successful and widely usable by more surgeons. Participants in this study will undergo segmental resection surgery with the aid of advanced technology. The study uses 3D VR models to plan the surgery, providing a clearer view of the lung's anatomy before and during the operation. Additionally, a special imaging technique using a substance called Indocyanine Green (ICG) is used to help map out the lung segments more accurately during surgery. This trial is in its early stages, known as Phase I, and aims to assess how safe and feasible this approach is and how quickly surgeons can learn to use this new technology. The study does not outline specific risks or benefits but focuses on improving the precision and success rate of lung surgeries.